{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:02:00Z","timestamp":1784127720325,"version":"3.55.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"CIBERehd","award":["EHD15PI05\/2016"],"award-info":[{"award-number":["EHD15PI05\/2016"]}]},{"name":"Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain","award":["PI16\/00598"],"award-info":[{"award-number":["PI16\/00598"]}]},{"name":"Spanish Ministry of Economy, Industry and Competitiveness","award":["SAF2016-75197-R"],"award-info":[{"award-number":["SAF2016-75197-R"]}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a, Spain","doi-asserted-by":"crossref","award":["Call 2015"],"award-info":[{"award-number":["Call 2015"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3n Samuel Sol\u00f3rzano Barruso, Spain","award":["FS\/7-2016"],"award-info":[{"award-number":["FS\/7-2016"]}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["DFG\/GRK 2015\/1"],"award-info":[{"award-number":["DFG\/GRK 2015\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Enrico and Enrica Sovena Foundation, Italy"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bbadis.2017.06.005","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T17:21:22Z","timestamp":1499448082000},"page":"1444-1453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"PB","title":["Chemoresistance and chemosensitization in cholangiocarcinoma"],"prefix":"10.1016","volume":"1864","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-6849","authenticated-orcid":false,"given":"Jose J.G.","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Herraez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitane","family":"Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta R.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2017.06.005_bb0005","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0010","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/gutjnl-2011-301748","article-title":"Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update","volume":"61","author":"Khan","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0015","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450116666150223121508","article-title":"Molecular bases of chemoresistance in cholangiocarcinoma","volume":"18","author":"Marin","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/092986710790514462","article-title":"Molecular bases of liver cancer refractoriness to pharmacological treatment","volume":"17","author":"Marin","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.20517\/2394-5079.2016.22","article-title":"Further understanding of mechanisms involved in liver cancer chemoresistance","volume":"3","author":"Briz","year":"2017","journal-title":"Hepatoma Res."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000453084","article-title":"Systemic therapy of cholangiocarcinoma","volume":"32","author":"Plentz","year":"2016","journal-title":"Visc. Med."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0035","doi-asserted-by":"crossref","first-page":"14957","DOI":"10.18632\/oncotarget.14844","article-title":"Intratumoral heterogeneity of intrahepatic cholangiocarcinoma","volume":"8","author":"Walter","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0040","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/mp300028a","article-title":"No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors","volume":"9","author":"Martinez-Becerra","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0045","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00280-011-1558-3","article-title":"Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients","volume":"68","author":"Hwang","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000151541","article-title":"Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines","volume":"54","author":"Namwat","year":"2008","journal-title":"Chemotherapy"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0055","first-page":"577","article-title":"Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy","volume":"6","author":"Xie","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0060","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/hep.26425","article-title":"Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib","volume":"58","author":"Herraez","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0065","doi-asserted-by":"crossref","first-page":"692071","DOI":"10.1155\/2013\/692071","article-title":"Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology","volume":"2013","author":"Lozano","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0070","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3892\/ijo.2013.1840","article-title":"Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma","volume":"42","author":"Lautem","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2407-12-109","article-title":"Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance","volume":"12","author":"Heise","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0080","doi-asserted-by":"crossref","first-page":"15846","DOI":"10.18632\/oncotarget.15029","article-title":"The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma","volume":"8","author":"Geier","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0085","doi-asserted-by":"crossref","first-page":"402","DOI":"10.2174\/156800912800190875","article-title":"Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs","volume":"12","author":"Marin","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0090","article-title":"Genetic and epigenetic bases of the relationship between reduced OCT1 expression and poor response to sorafenib in hepatocellular carcinoma and cholangiocarcinoma","volume":"S1","author":"Al-Abdulla","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0095","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4161\/cbt.11.9.15176","article-title":"The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer","volume":"11","author":"Wlcek","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drup.2016.06.005","article-title":"The impact of organic anion-transporting polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice","volume":"27","author":"Durmus","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/mol.116.105544","article-title":"Contribution of organic anion-transporting polypeptides 1A\/1B to doxorubicin uptake and clearance","volume":"91","author":"Lee","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0110","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","article-title":"Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide","volume":"19","author":"Zimmerman","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2362.2007.01916.x","article-title":"Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas","volume":"38","author":"Rau","year":"2008","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1535-7163.MCT-09-0663","article-title":"Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation","volume":"9","author":"Lagas","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0125","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3748\/wjg.v11.i18.2748","article-title":"Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines","volume":"11","author":"Tepsiri","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0130","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0959-8049(98)00142-7","article-title":"Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues","volume":"34","author":"Cao","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0135","first-page":"125","article-title":"High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma","volume":"13","author":"Srimunta","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0140","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1535-7163.MCT-04-0291","article-title":"The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites","volume":"4","author":"Pratt","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1535-7163.MCT-06-0529","article-title":"MRP8\/ABCC11 directly confers resistance to 5-fluorouracil","volume":"6","author":"Oguri","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4251\/wjgo.v5.i7.171","article-title":"Chemotherapy for cholangiocarcinoma: an update","volume":"5","author":"Ramirez-Merino","year":"2013","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0155","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.3748\/wjg.v18.i30.3955","article-title":"Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil","volume":"18","author":"Hahnvajanawong","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0160","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1097\/MD.0000000000000305","article-title":"Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series","volume":"93","author":"Kang","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-9966-33-11","article-title":"Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents","volume":"33","author":"Zeekpudsa","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0170","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-3-642-14541-4_8","article-title":"Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy","author":"Keppler","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0175","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1124\/jpet.103.052696","article-title":"Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-d-phenylglycine ethylester","volume":"306","author":"Nakajima","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0180","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.humpath.2009.01.026","article-title":"Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors)","volume":"40","author":"Schmitz","year":"2009","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0185","article-title":"Emerging molecular therapeutic targets for cholangiocarcinoma","author":"Rizvi","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0190","first-page":"577","article-title":"Thymosin beta10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma","volume":"15","author":"Sribenja","year":"2016","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0195","doi-asserted-by":"crossref","first-page":"e0142124","DOI":"10.1371\/journal.pone.0142124","article-title":"Sensitivity of human intrahepatic cholangiocarcinoma subtypes to chemotherapeutics and molecular targeted agents: a study on primary cell cultures","volume":"10","author":"Fraveto","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0200","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/gutjnl-2014-308810","article-title":"LTbetaR signalling preferentially accelerates oncogenic AKT-initiated liver tumours","volume":"65","author":"Scarzello","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0205","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0210","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13073-017-0431-3","article-title":"Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy","volume":"9","author":"Ahronian","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0215","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0220","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0225","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0230","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","article-title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"El-Khoueiry","year":"2012","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0235","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0240","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/bjc.2013.801","article-title":"S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma","volume":"110","author":"El-Khoueiry","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0245","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00535-011-0380-3","article-title":"Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells","volume":"46","author":"Sugiyama","year":"2011","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0250","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12029-008-9028-9","article-title":"Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report","volume":"38","author":"LaRocca","year":"2007","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0255","first-page":"E30","article-title":"Cholangiocarcinoma: treatment with sorafenib extended life expectancy to greater than four years","volume":"4","author":"Chakunta","year":"2013","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0260","doi-asserted-by":"crossref","first-page":"17246","DOI":"10.18632\/oncotarget.12825","article-title":"Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study","volume":"8","author":"Luo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0265","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3892\/mmr.2015.3589","article-title":"Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: potential drug synergism with gemcitabine","volume":"12","author":"Mayr","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0270","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0275","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","article-title":"Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma","volume":"22","author":"Moeini","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0280","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/156652410791608261","article-title":"Strategies for overcoming chemotherapy resistance in enterohepatic tumours","volume":"10","author":"Marin","year":"2010","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0285","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/1097-0215(20001015)88:2<287::AID-IJC22>3.0.CO;2-U","article-title":"Overcoming cisplatin resistance in vitro by a free and liposome-encapsulated bile acid derivative: BAMET-R2","volume":"88","author":"Briz","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0290","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/bjc.1992.217","article-title":"Reversal of multidrug resistance by surfactants","volume":"66","author":"Woodcock","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0295","doi-asserted-by":"crossref","first-page":"24995","DOI":"10.1016\/S0021-9258(19)73996-9","article-title":"Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles","volume":"267","author":"Sinicrope","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0300","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijpharm.2004.05.014","article-title":"Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats","volume":"280","author":"Choi","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0305","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.2174\/092986712803833362","article-title":"Immunoliposomes","volume":"19","author":"Paszko","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0310","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2174\/1389557513666131119202717","article-title":"Antibody-targeted immunoliposomes for cancer treatment","volume":"13","author":"Gao","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0315","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jconrel.2004.12.018","article-title":"Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor","volume":"103","author":"Lee","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0320","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1021\/nn200007z","article-title":"Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells","volume":"5","author":"Wang","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0325","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1053\/gast.1997.v113.pm9322525","article-title":"Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas","volume":"113","author":"Kullak-Ublick","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0330","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0168-8278(99)80046-4","article-title":"Further evidence of the usefulness of bile acids as molecules for shuttling cytostatic drugs toward liver tumors","volume":"31","author":"Monte","year":"1999","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0335","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0022-3565(24)29639-7","article-title":"Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors","volume":"297","author":"Dominguez","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0340","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2015.08.022","article-title":"Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)","volume":"216","author":"Lozano","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0345","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2003.10.008","article-title":"The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma","volume":"40","author":"Vavricka","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0350","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1478-3231.2005.01033.x","article-title":"Hepatobiliary transporter expression in human hepatocellular carcinoma","volume":"25","author":"Zollner","year":"2005","journal-title":"Liver Int."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0355","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16119","article-title":"Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1","author":"Herraez","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0360","first-page":"853","article-title":"Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells","volume":"61","author":"Briz","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0365","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2005.06.007","article-title":"Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma","volume":"44","author":"Lie","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0370","first-page":"1967","article-title":"Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil","volume":"41","author":"Tsuruo","year":"1981","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0375","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/BST0330241","article-title":"ABC transporters in the balance: is there a role in multidrug resistance?","volume":"33","author":"Polgar","year":"2005","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0380","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO;2-H","article-title":"A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar)","volume":"92","author":"Bates","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0385","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","article-title":"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999","volume":"116","author":"Cripe","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0390","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1475-2867-14-68","article-title":"Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines","volume":"14","author":"Hahnvajanawong","year":"2014","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0395","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3748\/wjg.v21.i4.1148","article-title":"beta-escin reverses multidrug resistance through inhibition of the GSK3beta\/beta-catenin pathway in cholangiocarcinoma","volume":"21","author":"Huang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0400","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11010-006-9302-8","article-title":"Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin","volume":"296","author":"Limtrakul","year":"2007","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/ph9040071","article-title":"Curcumin as a modulator of P-glycoprotein in cancer: challenges and perspectives","volume":"9","author":"Lopes-Rodrigues","year":"2016","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0410","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/j.2042-7158.2012.01549.x","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by astragaloside II","volume":"64","author":"Huang","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0415","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/1871520615666150113103439","article-title":"Development of fourth generation ABC inhibitors from natural products: a novel approach to overcome cancer multidrug resistance","volume":"15","author":"Karthikeyan","year":"2015","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0420","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3727\/096504015X14424348426071","article-title":"Inhibition of NF-kappaB activity enhances sensitivity to anticancer drugs in cholangiocarcinoma cells","volume":"23","author":"Seubwai","year":"2016","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0425","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.3892\/or.2014.3151","article-title":"Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines","volume":"31","author":"Ling","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0430","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i1.10","article-title":"Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers","volume":"19","author":"Kabanov","year":"2002","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0440","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1054\/bjoc.2001.2165","article-title":"Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion","volume":"85","author":"Batrakova","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0445","first-page":"897","article-title":"Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance","volume":"51","author":"Coon","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0450","unstructured":"B. Carreno-Gomez, R. Duncan, Compositions with enhanced oral bioavailability, in: U.S.P. application (Ed.), vol. US20030211072 A1, 2002."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0455","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2005.11.011","article-title":"Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine","volume":"111","author":"Werle","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0460","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ejpb.2009.03.008","article-title":"In vivo evaluation of thiolated poly(acrylic acid) as a drug absorption modulator for MRP2 efflux pump substrates","volume":"72","author":"Greindl","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0465","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2003.08.005","article-title":"Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles","volume":"93","author":"Vauthier","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0470","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/bjc.1997.362","article-title":"Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action","volume":"76","author":"de Verdiere","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0475","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2004.12.035","article-title":"Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo","volume":"42","author":"Barraud","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0480","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2009.01.021","article-title":"Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance","volume":"136","author":"Patil","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0485","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2006.09.007","article-title":"Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer","volume":"116","author":"Wong","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2017.06.005_bb0490","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","article-title":"Pharmacokinetics and biodistribution of nanoparticles","volume":"5","author":"Li","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbadis.2017.06.005_bb0495","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nrc4015","article-title":"Precision medicine for cancer with next-generation functional diagnostics","volume":"15","author":"Friedman","year":"2015","journal-title":"Nat. Rev. Cancer"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443917302004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443917302004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:46:52Z","timestamp":1760417212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443917302004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0925443917302004"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2017.06.005","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoresistance and chemosensitization in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2017.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}